menu
    • menu

    Company profile for Idorsia Pharmaceuticals

    NEW Drugs in Dev: 42
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core. Located in Switzerland – a biotech hub of Europe – Idorsia is specialized in the discovery and development ...
    The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core. Located in Switzerland – a biotech hub of Europe – Idorsia is specialized in the discovery and development of small molecules, to provide innovative therapeutic options.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Idorsia PharmaceuticalsSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Hegenheimermattweg 91 4123 Allschwil
    Telephone
    Telephone
    +41 58 844 00 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.idorsia.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Idorsia To Present Lucerastat Data At Worldsymposium
    Idorsia To Present Lucerastat Data At Worldsymposium

    30 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/30/3229223/0/en/Idorsia-to-present-long-term-lucerastat-data-and-kidney-biopsy-results-at-WORLDSymposium.html

    GLOBENEWSWIRE
    30 Jan 2026
    Share Share
    Idorsia Expands QUVIVIQ in Latin America via EMS
    Idorsia Expands QUVIVIQ in Latin America via EMS

    28 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/28/3227189/0/en/Global-expansion-of-Idorsia-s-QUVIVIQ-continues-with-EMS-partnership-for-Latin-America.html

    GLOBENEWSWIRE
    28 Jan 2026
    Share Share
    Idorsia Launches Oral First-In-Class CCR6 Antagonist Trial
    Idorsia Launches Oral First-In-Class CCR6 Antagonist Trial

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213308/0/en/Idorsia-initiates-a-proof-of-concept-trial-with-its-oral-first-in-class-selective-CCR6-antagonist.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    Idorsia's JERAYGO (Aprocitentan) Gains Approval In Canada
    Idorsia's JERAYGO (Aprocitentan) Gains Approval In Canada

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3212417/0/en/Idorsia-s-JERAYGO-aprocitentan-approved-in-Canada-for-the-treatment-of-resistant-hypertension.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Idorsia Advances Daridorexant For Insomnia In Menopausal Women
    Idorsia Advances Daridorexant For Insomnia In Menopausal Women

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3213054/0/en/Idorsia-s-daridorexant-in-women-during-menopausal-transition-age-with-insomnia.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Aprocitentan Shows Promise in CKD Hypertension Management
    Aprocitentan Shows Promise in CKD Hypertension Management

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3202900/0/en/New-Hypertension-publication-underscores-aprocitentan-s-potential-in-managing-hypertension-patients-with-CKD.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search